Observational study of azithromycin in hospitalized patients with COVID-19.
Identifieur interne : 000392 ( Main/Exploration ); précédent : 000391; suivant : 000393Observational study of azithromycin in hospitalized patients with COVID-19.
Auteurs : Alejandro Rodríguez-Molinero [Espagne] ; Carlos Pérez-L Pez [Espagne] ; César Gálvez-Barr N [Espagne] ; Antonio Mi Arro [Espagne] ; Oscar Macho [Espagne] ; Gabriela F. L Pez [Espagne] ; Maria Teresa Robles [Espagne] ; María Dolores Dapena [Espagne] ; Sergi Martínez [Espagne] ; Ezequiel Rodríguez [Espagne] ; Isabel Collado [Espagne]Source :
- PloS one [ 1932-6203 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Antibactériens (administration et posologie), Antibactériens (usage thérapeutique), Azithromycine (administration et posologie), Azithromycine (usage thérapeutique), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Sortie du patient (statistiques et données numériques), Sujet âgé (MeSH), Études cas-témoins (MeSH).
- MESH :
- administration et posologie : Antibactériens, Azithromycine.
- statistiques et données numériques : Sortie du patient.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antibactériens, Azithromycine.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Pandémies, Sujet âgé, Études cas-témoins.
English descriptors
- KwdEn :
- Aged (MeSH), Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (therapeutic use), Azithromycin (administration & dosage), Azithromycin (therapeutic use), Case-Control Studies (MeSH), Coronavirus Infections (drug therapy), Female (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Patient Discharge (statistics & numerical data), Pneumonia, Viral (drug therapy).
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Azithromycin.
- chemical , therapeutic use : Anti-Bacterial Agents, Azithromycin.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Patient Discharge.
- Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Pandemics.
Abstract
BACKGROUND
The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use of multiple therapeutic agents whose efficacy has not been previously demonstrated. The objective of this study was to analyze whether there is an association between the use of azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients hospitalized with COVID-19.
METHODS
This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxygen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to discharge. The results were compared between patients treated and untreated with the study drug through subcohort analyses matched for multiple clinical and prognostic factors, as well as through analysis of non-matched subcohorts, using Cox multivariate models adjusted for prognostic factors.
RESULTS
There were 239 patients treated with azithromycin. Of these, 29 patients treated with azithromycin could be matched with an equivalent number of control patients. In the analysis of these matched subcohorts, SAFI at 48h had no significant changes associated to the use of azithromycin, though azithromycin treatment was associated with a longer time to discharge (10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the increased hospital stay associated to azithromycin use, was no significant after adjustment using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88-2.41; p = 0.150). This study is limited by its small sample size and its observational nature; despite the strong pairing of the matched subcohorts and the adjustment of the Cox regression for multiple factors, the results may be affected by residual confusion.
CONCLUSIONS
We did not find a clinical benefit associated with the use of azithromycin, in terms of lung function 48 hours after treatment or length of hospital stay.
DOI: 10.1371/journal.pone.0238681
PubMed: 32881982
PubMed Central: PMC7470304
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Observational study of azithromycin in hospitalized patients with COVID-19.</title><author><name sortKey="Rodriguez Molinero, Alejandro" sort="Rodriguez Molinero, Alejandro" uniqKey="Rodriguez Molinero A" first="Alejandro" last="Rodríguez-Molinero">Alejandro Rodríguez-Molinero</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Perez L Pez, Carlos" sort="Perez L Pez, Carlos" uniqKey="Perez L Pez C" first="Carlos" last="Pérez-L Pez">Carlos Pérez-L Pez</name><affiliation wicri:level="1"><nlm:affiliation>Technical Research Center for Dependency Care and Autonomous Living (CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltru, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Technical Research Center for Dependency Care and Autonomous Living (CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltru</wicri:regionArea><wicri:noRegion>Vilanova i la Geltru</wicri:noRegion></affiliation></author><author><name sortKey="Galvez Barr N, Cesar" sort="Galvez Barr N, Cesar" uniqKey="Galvez Barr N C" first="César" last="Gálvez-Barr N">César Gálvez-Barr N</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Mi Arro, Antonio" sort="Mi Arro, Antonio" uniqKey="Mi Arro A" first="Antonio" last="Mi Arro">Antonio Mi Arro</name><affiliation wicri:level="3"><nlm:affiliation>Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Macho, Oscar" sort="Macho, Oscar" uniqKey="Macho O" first="Oscar" last="Macho">Oscar Macho</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="L Pez, Gabriela F" sort="L Pez, Gabriela F" uniqKey="L Pez G" first="Gabriela F" last="L Pez">Gabriela F. L Pez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Robles, Maria Teresa" sort="Robles, Maria Teresa" uniqKey="Robles M" first="Maria Teresa" last="Robles">Maria Teresa Robles</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Dapena, Maria Dolores" sort="Dapena, Maria Dolores" uniqKey="Dapena M" first="María Dolores" last="Dapena">María Dolores Dapena</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Martinez, Sergi" sort="Martinez, Sergi" uniqKey="Martinez S" first="Sergi" last="Martínez">Sergi Martínez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rodriguez, Ezequiel" sort="Rodriguez, Ezequiel" uniqKey="Rodriguez E" first="Ezequiel" last="Rodríguez">Ezequiel Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Collado, Isabel" sort="Collado, Isabel" uniqKey="Collado I" first="Isabel" last="Collado">Isabel Collado</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32881982</idno><idno type="pmid">32881982</idno><idno type="doi">10.1371/journal.pone.0238681</idno><idno type="pmc">PMC7470304</idno><idno type="wicri:Area/Main/Corpus">000356</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000356</idno><idno type="wicri:Area/Main/Curation">000356</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000356</idno><idno type="wicri:Area/Main/Exploration">000356</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Observational study of azithromycin in hospitalized patients with COVID-19.</title><author><name sortKey="Rodriguez Molinero, Alejandro" sort="Rodriguez Molinero, Alejandro" uniqKey="Rodriguez Molinero A" first="Alejandro" last="Rodríguez-Molinero">Alejandro Rodríguez-Molinero</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Perez L Pez, Carlos" sort="Perez L Pez, Carlos" uniqKey="Perez L Pez C" first="Carlos" last="Pérez-L Pez">Carlos Pérez-L Pez</name><affiliation wicri:level="1"><nlm:affiliation>Technical Research Center for Dependency Care and Autonomous Living (CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltru, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Technical Research Center for Dependency Care and Autonomous Living (CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltru</wicri:regionArea><wicri:noRegion>Vilanova i la Geltru</wicri:noRegion></affiliation></author><author><name sortKey="Galvez Barr N, Cesar" sort="Galvez Barr N, Cesar" uniqKey="Galvez Barr N C" first="César" last="Gálvez-Barr N">César Gálvez-Barr N</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Mi Arro, Antonio" sort="Mi Arro, Antonio" uniqKey="Mi Arro A" first="Antonio" last="Mi Arro">Antonio Mi Arro</name><affiliation wicri:level="3"><nlm:affiliation>Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Macho, Oscar" sort="Macho, Oscar" uniqKey="Macho O" first="Oscar" last="Macho">Oscar Macho</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="L Pez, Gabriela F" sort="L Pez, Gabriela F" uniqKey="L Pez G" first="Gabriela F" last="L Pez">Gabriela F. L Pez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Robles, Maria Teresa" sort="Robles, Maria Teresa" uniqKey="Robles M" first="Maria Teresa" last="Robles">Maria Teresa Robles</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Dapena, Maria Dolores" sort="Dapena, Maria Dolores" uniqKey="Dapena M" first="María Dolores" last="Dapena">María Dolores Dapena</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Martinez, Sergi" sort="Martinez, Sergi" uniqKey="Martinez S" first="Sergi" last="Martínez">Sergi Martínez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rodriguez, Ezequiel" sort="Rodriguez, Ezequiel" uniqKey="Rodriguez E" first="Ezequiel" last="Rodríguez">Ezequiel Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Collado, Isabel" sort="Collado, Isabel" uniqKey="Collado I" first="Isabel" last="Collado">Isabel Collado</name><affiliation wicri:level="3"><nlm:affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Anti-Bacterial Agents (administration & dosage)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Azithromycin (administration & dosage)</term><term>Azithromycin (therapeutic use)</term><term>Case-Control Studies (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Patient Discharge (statistics & numerical data)</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Antibactériens (administration et posologie)</term><term>Antibactériens (usage thérapeutique)</term><term>Azithromycine (administration et posologie)</term><term>Azithromycine (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Sortie du patient (statistiques et données numériques)</term><term>Sujet âgé (MeSH)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azithromycin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azithromycin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antibactériens</term><term>Azithromycine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Discharge</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Sortie du patient</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Azithromycine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Sujet âgé</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use of multiple therapeutic agents whose efficacy has not been previously demonstrated. The objective of this study was to analyze whether there is an association between the use of azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients hospitalized with COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxygen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to discharge. The results were compared between patients treated and untreated with the study drug through subcohort analyses matched for multiple clinical and prognostic factors, as well as through analysis of non-matched subcohorts, using Cox multivariate models adjusted for prognostic factors.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>There were 239 patients treated with azithromycin. Of these, 29 patients treated with azithromycin could be matched with an equivalent number of control patients. In the analysis of these matched subcohorts, SAFI at 48h had no significant changes associated to the use of azithromycin, though azithromycin treatment was associated with a longer time to discharge (10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the increased hospital stay associated to azithromycin use, was no significant after adjustment using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88-2.41; p = 0.150). This study is limited by its small sample size and its observational nature; despite the strong pairing of the matched subcohorts and the adjustment of the Cox regression for multiple factors, the results may be affected by residual confusion.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>We did not find a clinical benefit associated with the use of azithromycin, in terms of lung function 48 hours after treatment or length of hospital stay.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32881982</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Observational study of azithromycin in hospitalized patients with COVID-19.</ArticleTitle><Pagination><MedlinePgn>e0238681</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0238681</ELocationID><Abstract><AbstractText Label="BACKGROUND">The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use of multiple therapeutic agents whose efficacy has not been previously demonstrated. The objective of this study was to analyze whether there is an association between the use of azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients hospitalized with COVID-19.</AbstractText><AbstractText Label="METHODS">This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxygen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to discharge. The results were compared between patients treated and untreated with the study drug through subcohort analyses matched for multiple clinical and prognostic factors, as well as through analysis of non-matched subcohorts, using Cox multivariate models adjusted for prognostic factors.</AbstractText><AbstractText Label="RESULTS">There were 239 patients treated with azithromycin. Of these, 29 patients treated with azithromycin could be matched with an equivalent number of control patients. In the analysis of these matched subcohorts, SAFI at 48h had no significant changes associated to the use of azithromycin, though azithromycin treatment was associated with a longer time to discharge (10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the increased hospital stay associated to azithromycin use, was no significant after adjustment using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88-2.41; p = 0.150). This study is limited by its small sample size and its observational nature; despite the strong pairing of the matched subcohorts and the adjustment of the Cox regression for multiple factors, the results may be affected by residual confusion.</AbstractText><AbstractText Label="CONCLUSIONS">We did not find a clinical benefit associated with the use of azithromycin, in terms of lung function 48 hours after treatment or length of hospital stay.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodríguez-Molinero</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9678-2654</Identifier><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-López</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Technical Research Center for Dependency Care and Autonomous Living (CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltru, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gálvez-Barrón</LastName><ForeName>César</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miñarro</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macho</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López</LastName><ForeName>Gabriela F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robles</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dapena</LastName><ForeName>María Dolores</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>Ezequiel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collado</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Area, Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG), Sant Pere de Ribes, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 research group of CSAPG</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32881982</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0238681</ArticleId><ArticleId IdType="pii">PONE-D-20-19615</ArticleId><ArticleId IdType="pmc">PMC7470304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105924</Citation><ArticleIdList><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Jul - Aug;36:101791</Citation><ArticleIdList><ArticleId IdType="pubmed">32593867</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2020 Jun;48(6):e440-e469</Citation><ArticleIdList><ArticleId IdType="pubmed">32224769</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2018 Jun;51(6):918-924</Citation><ArticleIdList><ArticleId IdType="pubmed">29501821</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2007 Aug;132(2):410-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17573487</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Res. 2020 Jul 22;21(1):194</Citation><ArticleIdList><ArticleId IdType="pubmed">32698822</ArticleId></ArticleIdList></Reference><Reference><Citation>J Glob Antimicrob Resist. 2020 Jul 1;22:680-684</Citation><ArticleIdList><ArticleId IdType="pubmed">32622008</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Aug;97:396-403</Citation><ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Immunol Infect. 2019 Dec;52(6):872-879</Citation><ArticleIdList><ArticleId IdType="pubmed">31759853</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2019 Sep 16;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31527024</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2020 Jun;41(6):363-382</Citation><ArticleIdList><ArticleId IdType="pubmed">32291112</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Environ Res Public Health. 2020 Apr 14;17(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">32295188</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation><ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Immunol. 2019 Sep;63(9):343-349</Citation><ArticleIdList><ArticleId IdType="pubmed">31283028</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation><ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antibiot (Tokyo). 2019 Oct;72(10):759-768</Citation><ArticleIdList><ArticleId IdType="pubmed">31300721</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jul 23;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32706953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Rodriguez Molinero, Alejandro" sort="Rodriguez Molinero, Alejandro" uniqKey="Rodriguez Molinero A" first="Alejandro" last="Rodríguez-Molinero">Alejandro Rodríguez-Molinero</name></region><name sortKey="Collado, Isabel" sort="Collado, Isabel" uniqKey="Collado I" first="Isabel" last="Collado">Isabel Collado</name><name sortKey="Dapena, Maria Dolores" sort="Dapena, Maria Dolores" uniqKey="Dapena M" first="María Dolores" last="Dapena">María Dolores Dapena</name><name sortKey="Galvez Barr N, Cesar" sort="Galvez Barr N, Cesar" uniqKey="Galvez Barr N C" first="César" last="Gálvez-Barr N">César Gálvez-Barr N</name><name sortKey="L Pez, Gabriela F" sort="L Pez, Gabriela F" uniqKey="L Pez G" first="Gabriela F" last="L Pez">Gabriela F. L Pez</name><name sortKey="Macho, Oscar" sort="Macho, Oscar" uniqKey="Macho O" first="Oscar" last="Macho">Oscar Macho</name><name sortKey="Martinez, Sergi" sort="Martinez, Sergi" uniqKey="Martinez S" first="Sergi" last="Martínez">Sergi Martínez</name><name sortKey="Mi Arro, Antonio" sort="Mi Arro, Antonio" uniqKey="Mi Arro A" first="Antonio" last="Mi Arro">Antonio Mi Arro</name><name sortKey="Perez L Pez, Carlos" sort="Perez L Pez, Carlos" uniqKey="Perez L Pez C" first="Carlos" last="Pérez-L Pez">Carlos Pérez-L Pez</name><name sortKey="Robles, Maria Teresa" sort="Robles, Maria Teresa" uniqKey="Robles M" first="Maria Teresa" last="Robles">Maria Teresa Robles</name><name sortKey="Rodriguez, Ezequiel" sort="Rodriguez, Ezequiel" uniqKey="Rodriguez E" first="Ezequiel" last="Rodríguez">Ezequiel Rodríguez</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32881982
|texte= Observational study of azithromycin in hospitalized patients with COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32881982" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |